vs

Side-by-side financial comparison of Orthofix Medical Inc. (OFIX) and RADIANT LOGISTICS, INC (RLGT). Click either name above to swap in a different company.

RADIANT LOGISTICS, INC is the larger business by last-quarter revenue ($232.1M vs $219.9M, roughly 1.1× Orthofix Medical Inc.). RADIANT LOGISTICS, INC runs the higher net margin — 2.3% vs -1.0%, a 3.3% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -12.3%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $11.6M). Over the past eight quarters, RADIANT LOGISTICS, INC's revenue compounded faster (12.1% CAGR vs 8.0%).

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

Radiant Logistics, Inc. is a leading third-party logistics provider offering end-to-end supply chain solutions, domestic and international freight forwarding, warehousing, and last-mile delivery services. It primarily serves North American markets, with key client segments including retail, manufacturing, e-commerce, and industrial sectors, helping businesses optimize logistics workflows and cut operational costs.

OFIX vs RLGT — Head-to-Head

Bigger by revenue
RLGT
RLGT
1.1× larger
RLGT
$232.1M
$219.9M
OFIX
Growing faster (revenue YoY)
OFIX
OFIX
+14.2% gap
OFIX
2.0%
-12.3%
RLGT
Higher net margin
RLGT
RLGT
3.3% more per $
RLGT
2.3%
-1.0%
OFIX
More free cash flow
OFIX
OFIX
$5.2M more FCF
OFIX
$16.8M
$11.6M
RLGT
Faster 2-yr revenue CAGR
RLGT
RLGT
Annualised
RLGT
12.1%
8.0%
OFIX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
OFIX
OFIX
RLGT
RLGT
Revenue
$219.9M
$232.1M
Net Profit
$-2.2M
$5.3M
Gross Margin
71.1%
Operating Margin
0.2%
3.2%
Net Margin
-1.0%
2.3%
Revenue YoY
2.0%
-12.3%
Net Profit YoY
92.4%
-18.0%
EPS (diluted)
$-0.05
$0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OFIX
OFIX
RLGT
RLGT
Q4 25
$219.9M
$232.1M
Q3 25
$205.6M
$226.7M
Q2 25
$203.1M
$220.6M
Q1 25
$193.6M
$214.0M
Q4 24
$215.7M
$264.5M
Q3 24
$196.6M
$203.6M
Q2 24
$198.6M
$206.0M
Q1 24
$188.6M
$184.6M
Net Profit
OFIX
OFIX
RLGT
RLGT
Q4 25
$-2.2M
$5.3M
Q3 25
$-22.8M
$1.3M
Q2 25
$-14.1M
$4.9M
Q1 25
$-53.1M
$2.5M
Q4 24
$-29.1M
$6.5M
Q3 24
$-27.4M
$3.4M
Q2 24
$-33.4M
$4.8M
Q1 24
$-36.0M
$-703.0K
Gross Margin
OFIX
OFIX
RLGT
RLGT
Q4 25
71.1%
Q3 25
72.2%
Q2 25
68.7%
Q1 25
62.8%
Q4 24
69.0%
Q3 24
68.7%
Q2 24
67.8%
Q1 24
67.5%
Operating Margin
OFIX
OFIX
RLGT
RLGT
Q4 25
0.2%
3.2%
Q3 25
-8.3%
0.9%
Q2 25
-7.9%
2.4%
Q1 25
-25.2%
1.6%
Q4 24
-5.3%
3.3%
Q3 24
-9.6%
1.9%
Q2 24
-12.5%
2.4%
Q1 24
-15.6%
-0.5%
Net Margin
OFIX
OFIX
RLGT
RLGT
Q4 25
-1.0%
2.3%
Q3 25
-11.1%
0.6%
Q2 25
-6.9%
2.2%
Q1 25
-27.4%
1.2%
Q4 24
-13.5%
2.4%
Q3 24
-13.9%
1.7%
Q2 24
-16.8%
2.3%
Q1 24
-19.1%
-0.4%
EPS (diluted)
OFIX
OFIX
RLGT
RLGT
Q4 25
$-0.05
$0.11
Q3 25
$-0.57
$0.03
Q2 25
$-0.36
$0.10
Q1 25
$-1.35
$0.05
Q4 24
$-0.76
$0.13
Q3 24
$-0.71
$0.07
Q2 24
$-0.88
$0.11
Q1 24
$-0.95
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OFIX
OFIX
RLGT
RLGT
Cash + ST InvestmentsLiquidity on hand
$82.0M
$31.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$450.0M
$229.8M
Total Assets
$850.6M
$439.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OFIX
OFIX
RLGT
RLGT
Q4 25
$82.0M
$31.9M
Q3 25
$62.9M
$28.1M
Q2 25
$65.6M
$22.9M
Q1 25
$58.0M
$19.0M
Q4 24
$83.2M
$19.9M
Q3 24
$30.1M
$10.4M
Q2 24
$26.4M
$24.9M
Q1 24
$27.0M
$31.2M
Total Debt
OFIX
OFIX
RLGT
RLGT
Q4 25
Q3 25
$157.2M
Q2 25
$157.0M
Q1 25
$156.9M
Q4 24
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
OFIX
OFIX
RLGT
RLGT
Q4 25
$450.0M
$229.8M
Q3 25
$442.5M
$225.7M
Q2 25
$458.3M
$226.0M
Q1 25
$458.3M
$218.2M
Q4 24
$503.1M
$214.4M
Q3 24
$525.9M
$212.4M
Q2 24
$546.0M
$209.4M
Q1 24
$570.3M
$206.0M
Total Assets
OFIX
OFIX
RLGT
RLGT
Q4 25
$850.6M
$439.4M
Q3 25
$832.6M
$445.3M
Q2 25
$837.2M
$426.8M
Q1 25
$823.1M
$414.5M
Q4 24
$893.3M
$386.8M
Q3 24
$867.9M
$375.3M
Q2 24
$882.0M
$371.2M
Q1 24
$906.0M
$364.0M
Debt / Equity
OFIX
OFIX
RLGT
RLGT
Q4 25
Q3 25
0.36×
Q2 25
0.34×
Q1 25
0.34×
Q4 24
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OFIX
OFIX
RLGT
RLGT
Operating Cash FlowLast quarter
$27.7M
$12.4M
Free Cash FlowOCF − Capex
$16.8M
$11.6M
FCF MarginFCF / Revenue
7.6%
5.0%
Capex IntensityCapex / Revenue
4.9%
0.3%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$-1.3M
$8.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OFIX
OFIX
RLGT
RLGT
Q4 25
$27.7M
$12.4M
Q3 25
$12.4M
$2.5M
Q2 25
$11.6M
$3.1M
Q1 25
$-18.4M
$-5.7M
Q4 24
$23.7M
$15.7M
Q3 24
$11.7M
$205.0K
Q2 24
$9.0M
$1.3M
Q1 24
$-18.6M
$3.9M
Free Cash Flow
OFIX
OFIX
RLGT
RLGT
Q4 25
$16.8M
$11.6M
Q3 25
$2.5M
$977.0K
Q2 25
$4.5M
$2.2M
Q1 25
$-25.1M
$-6.4M
Q4 24
$15.2M
$14.1M
Q3 24
$6.3M
$-1.9M
Q2 24
$-360.0K
$-185.0K
Q1 24
$-29.1M
$1.8M
FCF Margin
OFIX
OFIX
RLGT
RLGT
Q4 25
7.6%
5.0%
Q3 25
1.2%
0.4%
Q2 25
2.2%
1.0%
Q1 25
-13.0%
-3.0%
Q4 24
7.0%
5.3%
Q3 24
3.2%
-0.9%
Q2 24
-0.2%
-0.1%
Q1 24
-15.4%
1.0%
Capex Intensity
OFIX
OFIX
RLGT
RLGT
Q4 25
4.9%
0.3%
Q3 25
4.8%
0.7%
Q2 25
3.5%
0.4%
Q1 25
3.5%
0.3%
Q4 24
4.0%
0.6%
Q3 24
2.7%
1.0%
Q2 24
4.7%
0.7%
Q1 24
5.6%
1.2%
Cash Conversion
OFIX
OFIX
RLGT
RLGT
Q4 25
2.33×
Q3 25
1.90×
Q2 25
0.63×
Q1 25
-2.26×
Q4 24
2.43×
Q3 24
0.06×
Q2 24
0.26×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

RLGT
RLGT

Transferred Over Time$201.2M87%
Other$25.0M11%
Value Added Services$4.2M2%
Transferred At Point In Time$1.8M1%

Related Comparisons